MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT…
MaaT PharmaMarch 17, 2022
Ce communiqué ne peut être distribué directement ou indirectement aux Etats-Unis d’Amérique, au Canada, en…
MaaT PharmaFebruary 9, 2022
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem…
MaaT PharmaFebruary 8, 2022
MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the…
MaaT PharmaJanuary 26, 2022
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of…
MaaT PharmaJanuary 24, 2022
Alliance Promotion Microbiote devient une Association et poursuit la structuration de la filière française du…
MaaT PharmaJanuary 20, 2022
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022 Important clinical milestones are expected…
MaaT PharmaJanuary 17, 2022
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe…
MaaT PharmaJanuary 13, 2022
Lyon, France, January 3, 2022 - 7:00 pm CET – MaaT Pharma (EURONEXT: MAAT -…
MaaT PharmaJanuary 3, 2022
